Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2014—TriLink BioTechnologies has signed a licensing agreement with Biofortuna for use of its CleanAmp dNTPs in Biofortuna’s freeze-drying (lyophilized) contract development and production service.
January 2014—Abbott received FDA approval to expand the use of its RealTime HCV and RealTime HBV assay to run on its m2000 RealTime System. The new mPlus makes it possible for laboratories of any size to perform molecular diagnostic tests for infectious disease detection and therapy monitoring. It also enhances the Abbott m2000’s flexibility and makes molecular testing easier and more efficient.
January 2014—Zenalux Biomedical has improved measurement reproducibility in its Zenascope system by adding pressure-sensing capability to its optical probe. The system now allows users to dial in a target pressure for each measurement via the user interface. After probe-to-tissue contact is made, the user interface monitors pressure feedback from the tip of the optical probe, facilitating data collection at the desired contact pressure.
January 2014—The FDA has approved Hologic’s Aptima HPV 16 18/45 genotype assay for use on its fully automated Panther system. The Aptima HPV 16 18/45 genotype assay is performed using Hologic’s ThinPrep liquid cytology specimen and is intended to test specimens from women with Aptima HPV assay-positive results. The addition of HPV genotype 45 is designed to help identify more women at risk for adenocarcinoma, with minimal impact to colposcopy rates.
January 2014—Ventana Medical Systems launched the Ventana Gram Staining Kit. Automated for use on the Ventana BenchMark Special Stains instrument, the kit aids pathologists in the most basic classification of bacteria into gram-positive and gram-negative bacteria in fixed tissue samples.
January 2014—Norwegian molecular diagnostics company Genetic Analysis has launched its GA-map IBS Dysbiosis Test. The DNA-based test makes it possible to effectively and routinely analyze the composition of the gut microbiota (bacteria profile) and any dysbiosis. The GA-map IBS Dysbiosis Test can be run in any molecular diagnostics laboratory. Target DNA is first isolated from patient stool samples. Then conserved regions of the bacterial 16S rRNA gene are used as templates to amplify the more variable regions in-between that are
December 2013—Biosearch Technologies has acquired a majority stake in LightSpeed Genomics, a company developing an innovative optical-detection solution for the life science and diagnostics industry based on its proprietary Synthetic Aperture Optics (SAO) technology. Biosearch and LightSpeed are collaborators on the development of StellarVision, a next-generation gene-expression platform optimized to work seamlessly with Biosearch’s Stellaris RNA FISH assays to detect and quantify single-molecule RNA targets within individual cells.
December 2013—The Society for Laboratory Automation and Screening, an international community of more than 15,000 scientists, engineers, researchers, technologists, and others from academic, government, and commercial laboratories, announced the opening of a European office in Brussels, Belgium. SLAS’ European office becomes the society’s third on three continents, joining operations in Shanghai, China, and its global headquarters in the United States.
December 2013—Ventana Medical Systems has entered into an agreement with Incyte to collaborate on the development of companion diagnostic tests for Incyte’s oncology drug programs, beginning with the Incyte IDO1 inhibitor program.
December 2013—Mettler Toledo released the latest version of its interactive, Web-based Electrode ValueBox. This downloadable electrode identification and troubleshooting toolkit features a revised electronic sensor product guide to help Mettler Toledo customers choose the right electrode, saving time and enhancing accuracy when pH and other values are critical to experiment outcomes and product consistency.
